Nath Bio-Genes Intrinsic Value
Nath Bio-Genes (NATHBIOGEN) median intrinsic value is ₹101.05 from 4 valuation models (range ₹78–₹339), vs current price ₹147.34 — -31.4% downside (Trading Above Calculated Value), margin of safety -45.8%. Check Nath Bio-Genes market cap to track the company's total market size over time.
NATHBIOGEN Valuation Methods Summary — DCF, Graham Number & P/E
Nath Bio-Genes intrinsic value across 4 models vs current price ₹147.34 — upside/downside and value range per method. For current market price and key ratios, visit NATHBIOGEN stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹338.95 | ₹305.06 - ₹372.85 | +130.0% | Book Value/Share: ₹338.95, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹92.63 | ₹83.37 - ₹101.89 | -37.1% | Revenue/Share: ₹115.79, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹101.05 | ₹90.94 - ₹111.16 | -31.4% | EBITDA: ₹32.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹77.93 | ₹62.34 - ₹93.52 | -47.1% | CF Growth: 1.9%, Discount: 15% |
NATHBIOGEN Intrinsic Value vs Market Price — All Valuation Models
Nath Bio-Genes fair value range ₹78–₹339 vs current market price ₹147.34 across 4 valuation models. See Nath Bio-Genes P/B valuation to compare market price against book value per share.
NATHBIOGEN Intrinsic Value Analysis — Undervalued or Overvalued?
Nath Bio-Genes median intrinsic value ₹101.05, current price ₹147.34 — Trading Above Calculated Value by 31.4%, margin of safety -45.8%.
What is the intrinsic value of NATHBIOGEN?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Nath Bio-Genes (NATHBIOGEN) is ₹101.05 (median value). With the current market price of ₹147.34, this represents a -31.4% variance from our estimated fair value.
The valuation range spans from ₹77.93 to ₹338.95, indicating ₹77.93 - ₹338.95.
Is NATHBIOGEN undervalued or overvalued?
Based on our multi-method analysis, Nath Bio-Genes (NATHBIOGEN) appears to be trading above calculated value by approximately 31.4%.
NATHBIOGEN Financial Health — Key Ratios vs Industry Benchmarks
Nath Bio-Genes financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 40.59 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.21x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NATHBIOGEN Cash Flow Quality — Operating & Free Cash Flow
Nath Bio-Genes operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹18 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹75 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹38 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |